Abstract: Fluorescence in situ hybridization is a molecular cytogenetic diagnostic technique, which can provide a more accurate basis for pathological diagnosis and clinical treatment. This technique has been widely used in the diagnosis and treatment of multiple myeloma but has not been widely used in systemic light chain (AL)  amyloidosis. This article will review the effects of common types of cytogenetic abnormalities on the choice of treatment and survival prognosis of patients.

Key words:  systemic light chain amyloidosis   , florescence in situ hybridization   , therapy